Yilin Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yilin Yang has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Xiao Yun Xu
Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, United Kingdom
2 shared publications - Boram Gu
School of Chemical Engineering, Chonnam National University, 77 Yongbong-ro, Buk-gu, Gwangju, Republic of Korea
1 shared publication - Boram Gu
School of Chemical Engineering, Chonnam National University, 77 Yongbong-Ro, Buk-Gu, Gwangju 61186, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 13 February 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 171, 108141
In silico study of combination thrombolytic therapy with alteplase and mutant pro-urokinase for fibrinolysis in ischemic stroke
- 13 February 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 171, 108141
Open AccessIn silico study of combination thrombolytic therapy with alteplase and mutant pro-urokinase for fibrinolysis in ischemic stroke
- Open Access
- 28 February 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 797
In Silico Study of Different Thrombolytic Agents for Fibrinolysis in Acute Ischemic Stroke
Alteplase is the only FDA-approved drug for thrombolysis in acute ischemic stroke (AIS). Meanwhile, several thrombolytic drugs are deemed to be promising candidates to substitute alteplase. This paper evaluates the efficacy and safety of urokinase, ateplase, tenecteplase, and reteplase for intravenous AIS therapy by computational simulations of the pharmacokinetics and pharmacodynamics combined with a local fibrinolysis model. The performances of the drugs are evaluated by comparing clot lysis time, plasminogen activator inhibitor (PAI) inhibition resistance, intracranial hemorrhage (ICH) risk, and activation time from drug administration to clot lysis. Our results reveal that urokinase has the quickest lysis completion but the highest ICH risk due to excess fibrinogen depletion in systemic plasma. While tenecteplase and alteplase have very similar thrombolysis efficacy, tenecteplase has a lower risk of ICH and better resistance to PAI-1. Among the four simulated drugs, reteplase has the slowest fibrinolysis rate, but fibrinogen concentration in systemic plasma is unaffected during thrombolysis.
- 28 February 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 797
Open AccessIn Silico Study of Different Thrombolytic Agents for Fibrinolysis in Acute Ischemic Stroke
Alteplase is the only FDA-approved drug for thrombolysis in acute ischemic stroke (AIS). Meanwhile, several thrombolytic drugs are deemed to be promising candidates to substitute alteplase. This paper evaluates the efficacy and safety of urokinase, ateplase, tenecteplase, and reteplase for intravenous AIS therapy by computational simulations of the pharmacokinetics and pharmacodynamics combined with a local fibrinolysis model. The performances of the drugs are evaluated by comparing clot lysis time, plasminogen activator inhibitor (PAI) inhibition resistance, intracranial hemorrhage (ICH) risk, and activation time from drug administration to clot lysis. Our results reveal that urokinase has the quickest lysis completion but the highest ICH risk due to excess fibrinogen depletion in systemic plasma. While tenecteplase and alteplase have very similar thrombolysis efficacy, tenecteplase has a lower risk of ICH and better resistance to PAI-1. Among the four simulated drugs, reteplase has the slowest fibrinolysis rate, but fibrinogen concentration in systemic plasma is unaffected during thrombolysis.